Join CARGO’s President and CEO Gina Chapman for a fireside chat at the Jefferies Global Healthcare Conference in New York City, on June 5 at 11:30 a.m. EST, where she will share our latest company highlights. Learn more here: https://lnkd.in/exiE5HCA #CART #JefferiesHealthcare #celltherapy
CARGO Therapeutics
Biotechnology Research
San Carlos, California 11,985 followers
Outsmarting Cancer to Deliver More Cures
About us
CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.
- Website
-
https://cargo-tx.com
External link for CARGO Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Carlos, California
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
835 Industrial Rd, Suite 400
San Carlos, California 94070, US
Employees at CARGO Therapeutics
-
Bethany Rogers
Results-driven cell therapy leader passionate about building an engaging culture, developing high-performing teams, and delivering impactful health…
-
Angela Haasch
Results driven, self-motivated professional with solid experience supporting executives in a fast pace environment.
-
Brett Masterson
Head of Marketing
-
Christophe Suchet
VP, Head of IT at CARGO Therapeutics
Updates
-
CARGO Therapeutics reposted this
We’re pleased to announce the appointment of Jane Pritchett Henderson to our Board of Directors, adding strategic finance and broad biotech operating experience as we continue to execute our potentially pivotal Phase 2, FIRCE-1 clinical study, while advancing our CAR T pipeline. Learn more: https://lnkd.in/eQWfU3yc #CART #celltherapy
-
-
We’re pleased to announce the appointment of Jane Pritchett Henderson to our Board of Directors, adding strategic finance and broad biotech operating experience as we continue to execute our potentially pivotal Phase 2, FIRCE-1 clinical study, while advancing our CAR T pipeline. Learn more: https://lnkd.in/eQWfU3yc #CART #celltherapy
-
-
At CARGO, we are tenacious in the relentless pursuit of our mission to develop potentially curative treatments for more patients. We’re currently hiring an Associate Director, Statistical Programming, who will play a critical role in advancing our clinical development programs. Learn more: https://lnkd.in/e5UWD84e #biotechjobs #careers #CART
-
-
Today we announced a $110 million private placement equity financing with participation from new and existing leading healthcare investors. This financing will support BLA preparation for our potentially pivotal Phase 2 study FIRCE-1 of firi-cel and IND-enabling studies for CRG-023, our novel tri-specific CAR T. Learn more: https://lnkd.in/ec5_ydUm #CART #celltherapy #oncology
-
-
We’re hiring a Scientist, Discovery, to join our growing team! At CARGO, we are focused on developing next-generation CAR T-cell therapies to outsmart cancer and deliver more cures. In this role, you’ll have the opportunity to make an impact from the start. Learn more: https://lnkd.in/ezFdb7Ds #biotechjobs #CART #celltherapy
-
-
We are proud to be named one of BioSpace’s NextGen Class of 2024: Top Life Sciences Startups to Watch This Year! Our clinical-stage CD22 CAR T-cell therapy and platform technologies uniquely position us to engineer, develop and deliver next-generation CAR T-cell therapies with curative potential. We are laser-focused on bringing forward this technology to make an impact for patients. Read more: https://bit.ly/4au6nmW #CART #celltherapy #oncology
-
We’re thrilled to see ongoing follow-up from Stanford’s Phase 1 study for firi-cel to be presented at European Hematology Association (EHA)’s 2024 Congress in June. This important data continues to highlight the impressive efficacy, durability and safety profile of firi-cel, supporting its curative potential for patients with large b-cell lymphoma whose disease has relapsed or was refractory to CD19 CAR T-cell therapy. Learn more: https://bit.ly/4bCMRFn #celltherapy #CART
-
-
Today we reported our first quarter 2024 financial results and provided a business update, including progress on enrollment for our potentially pivotal Phase 2 clinical study for our lead CAR T-cell therapy candidate, firi-cel. Learn more: https://bit.ly/4bCMRFn #celltherapy #CART
-
-
At CARGO, our mission is to outsmart cancer by developing the next generation of transformational CAR T-cell therapies to impact patients worldwide—and we’re growing our team! We’re currently searching for a Senior Manager, Supply Chain Planning, to join our technical operations organization and play a critical role in all aspects of capacity and supply assessment. Learn more about this opportunity to join our team: https://lnkd.in/gJkTR2v4 #biotechjobs #CART #celltherapy #supplychain
-